PHIO PHARMACEUTICALS CORP. 8-K Summary (Oct 31, 2025)

PHIO announced key Board governance changes:

• Director Robert Ferrara resigned from the Board, including Audit and Compensation Committees, and as Lead Independent Director. > His departure was stated as not resulting from any disagreement with the Company.
• The Board size was reduced from six to five members.
• David Deming was appointed as the new Lead Independent Director.

This report reflects material management structure adjustments. PHIO common stock trades under PHIO on The Nasdaq Capital Market.